Trial Profile
A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Aducanumab (Primary) ; Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Biogen
- 24 Aug 2022 Status changed from active, no longer recruiting to completed.
- 19 May 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2022 Status changed from not yet recruiting to recruiting.